Last updated: February 15, 2026
What is Asoprisnil and its current development status?
Asoprisnil is a selective progesterone receptor modulator (SPRM) developed by Pfizer. It was designed for applications including uterine fibroids, endometriosis, and breast cancer. The drug's development has faced multiple delays, with Pfizer halting new clinical trials in 2011 and transferring the program to specialty pharma companies for further pursuit. Currently, no active clinical trials are ongoing for Asoprisnil as of 2023 ([1]).
How has Asoprisnil progressed through clinical development?
Pfizer initiated Phase II trials for uterine fibroids and endometriosis with promising results before halting the program due to safety concerns, primarily liver-related adverse events. The drug's development has been largely paused since 2011. Efforts to reintroduce the candidate have not been publicly reported, indicating that the drug remains inactive in the pipeline.
What are the market prospects for Asoprisnil in its potential indications?
Uterine Fibroids Market
Estimated global market value: $4.5 billion in 2023, projected to grow at a CAGR of 4.2% through 2030 ([2]). Existing therapies include GnRH agonists, selective progesterone receptor modulators (like ulipristal acetate), and surgical interventions.
Endometriosis Market
Market size: approximately $1.8 billion in 2023, with projected CAGR over 6% ([3]). Treatments are mainly hormonal, with limited options for long-term management.
Breast Cancer Segment
Potential applications are speculative due to lack of clinical development. The estrogen receptor and progesterone receptor pathways are targeted with existing drugs, but Asoprisnil's safety profile limited its pursuit.
Competitive Landscape
Pfizer's withdrawal created a gap for verified SPRMs. Newer compounds like relugestrel and ulipristal acetate occupy segments for fibroids and endometriosis. The safety profile, especially regarding liver toxicity, limits the adoption of candidates with similar adverse profiles.
Future Market Projection
Given its current inactivity, Asoprisnil's direct market opportunity appears minimal unless new safety or efficacy data emerge. Companies focusing on SPRMs continue to explore alternatives, but Asoprisnil itself is unlikely to re-enter development soon.
What are the key challenges impacting Asoprisnil's market outlook?
- Safety concerns: Liver toxicity led Pfizer to cease development, creating an industry caution around similar SPRMs.
- Regulatory hurdles: Re-establishing safety profiles would require extensive trials, hindering rapid re-entry.
- Market competition: Multiple approved and late-stage pipeline drugs reduce unmet needs that Asoprisnil could address.
- Intellectual property and licensing: Pfizer holds the initial patents; licensing negotiations or patent expirations could influence future development.
What are the strategic considerations for stakeholders?
- For investors: The drug's inactive status diminishes near-term upside unless a third party acquires rights and commits to safety re-evaluation.
- For biotech firms: Developing new SPRMs with improved safety profiles could target the same indications, bypassing Asoprisnil's limitations.
- For Pfizer: The company maintains potential control over the compound's future but shows no active plans publicly.
Key Takeaways
- Asoprisnil was advanced into Phase II trials but has not progressed further since 2011 due to safety issues.
- The current market landscape favors newer SPRMs with better safety profiles; Asoprisnil remains inactive.
- The potential for reactivation depends on overcoming safety hurdles, which historically have been significant.
- The uterine fibroids and endometriosis markets are growing, but competition and safety concerns limit opportunities for Asoprisnil.
- Strategic moves involve licensing, reformulation, or new safety evaluations, though none are imminent.
FAQs
1. Is Asoprisnil currently in clinical development?
No. Pfizer ceased development around 2011, and there are no public reports of ongoing clinical trials.
2. Could Asoprisnil return to the market?
Possible if new safety data support its re-entry, but this would require substantial investment and regulatory approval.
3. What drugs compete with Asoprisnil?
Ulipristal acetate (approved in some markets) and relugestrel are notable competitors targeting similar indications.
4. Why did Pfizer halt Asoprisnil's development?
Due to safety concerns, primarily liver toxicity observed in trials.
5. What lessons can new SPRMs learn from Asoprisnil's development?
Prioritize safety profiling early; safety concerns can halt otherwise promising candidates and impact market prospects.
References:
[1] Pfizer. "Clinical Trial Information for Asoprisnil." 2011.
[2] MarketsandMarkets. "Uterine Fibroids Market." 2023.
[3] Grand View Research. "Endometriosis Market Size & Growth." 2023.
